相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma
Amin H. Nassar et al.
BRITISH JOURNAL OF CANCER (2020)
EGR1 Transcription Factor is a Multifaceted Regulator of Matrix Production in Tendons and Other Connective Tissues
Emmanuelle Havis et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study.
Matt D. Galsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
Matthew D. Galsky et al.
LANCET (2020)
Mesenchymal and MAPK Expression Signatures Associate with Telomerase Promoter Mutations in Multiple Cancers
Josh Lewis Stern et al.
MOLECULAR CANCER RESEARCH (2020)
Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma
Matthew Kyle Labriola et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
Nazli Dizman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Predictive Biomarkers of Response to Immunotherapy in Metastatic Renal Cell Cancer
Alessandra Raimondi et al.
FRONTIERS IN ONCOLOGY (2020)
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
Jacqueline Vuky et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
Thomas Powles et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment
Huahua Li et al.
CANCER MEDICINE (2020)
Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review
Jean-Michel Lavoie et al.
JOURNAL OF UROLOGY (2019)
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Y. Loriot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
1192OAssociation of tumour mutational burden with outcomes in patients with select advanced solid tumours treated with pembrolizumab in KEYNOTE-158
A Marabelle et al.
ANNALS OF ONCOLOGY (2019)
Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma
Chuanjie Zhang et al.
ANNALS OF TRANSLATIONAL MEDICINE (2019)
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy
Daniel L. Suzman et al.
ONCOLOGIST (2019)
Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer
Viktoria Stuehler et al.
WORLD JOURNAL OF UROLOGY (2019)
Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma
Sumit Isharwal et al.
EUROPEAN UROLOGY FOCUS (2019)
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
Min Yuen Teo et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Manish R. Patel et al.
LANCET ONCOLOGY (2018)
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott et al.
NATURE MEDICINE (2018)
Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis
Cagatay Guenes et al.
NATURE REVIEWS UROLOGY (2018)
Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma
Vadim S. Koshkin et al.
CURRENT ONCOLOGY REPORTS (2018)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V. Balar et al.
LANCET (2017)
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V. Balar et al.
LANCET ONCOLOGY (2017)
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study
Thomas Powles et al.
JAMA ONCOLOGY (2017)
A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition
Milena P. Mak et al.
CLINICAL CANCER RESEARCH (2016)
Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma
Guru Sonpavde et al.
JOURNAL OF UROLOGY (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Derepression of hTERT gene expression promotes escape from oncogene-induced cellular senescence
Priyanka L. Patel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-up
Rossana Critelli et al.
ONCOTARGET (2016)
TERT promoter mutations and telomerase reactivation in urothelial cancer
Sumit Borah et al.
SCIENCE (2015)
Telomerase Reverse Transcriptase Gene Promoter Mutations Help Discern the Origin of Urogenital Tumors: A Genomic and Molecular Study
Song Wu et al.
EUROPEAN UROLOGY (2014)
Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with Outcome
Yves Allory et al.
EUROPEAN UROLOGY (2014)
Comprehensive molecular characterization of urothelial bladder carcinoma
John N. Weinstein et al.
NATURE (2014)
TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR
Kun Wang et al.
ONCOTARGET (2014)
Prognostic Model for Predicting Survival of Patients With Metastatic Urothelial Cancer Treated With Cisplatin-Based Chemotherapy
Andrea B. Apolo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens
Joaquim Bellmunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
分享论文
